Sinopharm Of China To Buy Le Ren For $197.4 Million In Growth Move
This article was originally published in PharmAsia News
Executive Summary
China's Sinopharm said its broad acquisition plans include buying a 60 percent stake in Shijiazhuang Le Ren Pharmaceutical for a maximum of $197.4 million